KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Depreciation & Amortization (CF): 2011-2025

Historic Depreciation & Amortization (CF) for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $24.8 million.

  • Supernus Pharmaceuticals' Depreciation & Amortization (CF) rose 23.40% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.4 million, marking a year-over-year increase of 2.58%. This contributed to the annual value of $80.4 million for FY2024, which is 5.24% down from last year.
  • Supernus Pharmaceuticals' Depreciation & Amortization (CF) amounted to $24.8 million in Q3 2025, which was up 16.14% from $21.4 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $24.8 million during Q3 2025, with a 5-year trough of $6.6 million in Q1 2021.
  • Over the past 3 years, Supernus Pharmaceuticals' median Depreciation & Amortization (CF) value was $20.7 million (recorded in 2023), while the average stood at $21.1 million.
  • Data for Supernus Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY increase of 280.60% (in 2021) and a maximum YoY decrease of 14.89% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Depreciation & Amortization (CF) stood at $12.7 million in 2021, then surged by 64.07% to $20.8 million in 2022, then climbed by 3.97% to $21.7 million in 2023, then dropped by 13.06% to $18.8 million in 2024, then climbed by 23.40% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q3 2025, $21.4 million for Q2 2025, and $20.4 million during Q1 2025.